Table of Contents
Pharmaceuticals in North America industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in North America
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in North America
Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the North America pharmaceuticals market with five year forecasts
Essential resource for top-line data and analysis covering the North America pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Reasons To Buy
What was the size of the North America pharmaceuticals market by value in 2015?
What will be the size of the North America pharmaceuticals market in 2020?
What factors are affecting the strength of competition in the North America pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitors in North America's pharmaceuticals market?
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2015 annual average exchange rates.
The North American pharmaceuticals market had total revenues of $411.4bn in 2015, representing a compound annual growth rate (CAGR) of 2.2% between 2011 and 2015.
While the US and Canada are highly developed markets they have different growth drivers. Canada is attempting to reduce its pharmaceutical spending, and increase generic capacity in the market to do so in order to reduce the burden on state health budgets, which does inhibit growth in general. The US is a huge market, on the other hand, and maintains good growth consistently despite its developed nature due to the very strong private health sector.
The performance of the market is forecast to accelerate, with an anticipated CAGR of 2.4% for the five-year period 2015 - 2020, which is expected to drive the market to a value of $463.9bn by the end of 2020.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...
PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...